Updated CADTH Reimbursement Recommendations From a Streamlined Drug Class or Therapeutic Review

March 30, 2022 Conditions for reimbursement Initiation: For patients who are Initiation: Eligibility for reimbursement biologic-naive who have yet to be of bimekizumab should be based on treated with any biologic, a drug the criteria used by each of the public from the anti-IL-17 or anti-IL-23 drug plans for reimbursement of other class should be trialled before IL-17 inhibitors for the treatment. [...] Conditions for reimbursement Initiation: For patients who are Initiation: Eligibility for tildrakizumab biologic-naive who have yet to be should be based on the criteria used treated with any biologic, a drug by each of the public drug plans for from the anti-IL-17 or anti-IL-23 reimbursement of other biologics for class should be trialled before moderate-to-severe plaque psoriasis. [...] class should be trialled before The drug plan cost for risankizumab a drug from the anti-TNF or should not exceed the drug plan cost of anti-IL-12/23 class (if the FMEC treatment with the least costly biologic pricing condition is met). [...] biologic-naive who have yet to be Condition: The drug plan cost for treated with any biologic, a drug secukinumab should not exceed the drug from the anti-IL-17 or anti-IL-23 plan cost of the least costly biologic class should be trialled before reimbursed for the treatment of moderate a drug from the anti-TNF or to severe plaque psoriasis. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.